Advertisement
Advertisement

NKTR

NKTR logo

Nektar Therapeutics

67.17
USD
Sponsored
-1.15
-1.68%
Jul 14, 16:00 UTC -4
Closed
exchange

After-Market

67.26

+0.09
+0.13%

NKTR Earnings Reports

Positive Surprise Ratio

NKTR beat 33 of 42 last estimates.

79%

Next Report

Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$10.59M
/
-$2.07
Implied change from Q1 26 (Revenue/ EPS)
-2.52%
/
+13.74%
Implied change from Q2 25 (Revenue/ EPS)
-5.26%
/
-29.83%

Nektar Therapeutics earnings per share and revenue

On May 07, 2026, NKTR reported earnings of -1.82 USD per share (EPS) for Q1 26, missing the estimate of -1.62 USD, resulting in a -11.88% surprise. Revenue reached 10.86 million, compared to an expected 10.85 million, with a 0.11% difference. The market reacted with a -1.78% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -2.07 USD, with revenue projected to reach 10.59 million USD, implying an increase of 13.74% EPS, and decrease of -2.52% in Revenue from the last quarter.
FAQ
For Q1 2026, Nektar Therapeutics reported EPS of -$1.82, missing estimates by -11.88%, and revenue of $10.86M, 0.11% above expectations.
The stock price moved down -1.78%, changed from $83.37 before the earnings release to $81.89 the day after.
The next earning report is scheduled for Aug 06, 2026.
Based on 8 analysts, Nektar Therapeutics is expected to report EPS of -$2.07 and revenue of $10.59M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement